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response in rats
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ABSTRACT Antibodies were raised in rats against the polio-
virus type 1 capsid proteins, VP1, VP2, and VP3. Antibodies di-
rected against VP1 from type 1 poliovirus (Mahoney) neutralized
type 1 but not type 2 poliovirus. Antibodies raised against VP2 and
VP3 failed to neutralize type 1 virus. Thus, VP1 appears to be a
neutralizing antigen for poliovirus and in its denatured form pre-
sents to the immune system its neutralizing determinants.
The poliovirion has been shown to exist in two basic antigenic
forms, N (or D) and C (or H), that are not crossreactive. The
N antigenic form is associated with mature infectious virus (1).
C antigenicity is observed in empty capsids isolated from in-
fected cells, in mature virions that have been heated, modified,
or degraded, and in virions that were bound to and eluted from
membranes of suspectible cells (2-6). By using nonsusceptible
animals for immunization, neutralizing sera have been found
to recognize the N antigenic state and have been obtained only
when native virions are injected. These neutralizing sera bind
to native virions but do not recognize C antigenic structures.
Similarly, C-antigen-specific antibodies recognize heated or
disrupted virions and procapsid structures but do not bind to
native virions (7-8). Recently, a hybridoma cell line producing
neutralizing monoclonal antibodies has been generated from
mice that were injected with native virions (9). In addition to
binding to native virions, this antibody recognizes the 70S pro-
capsid and the 14S assembly subunit, indicating that subunits
of the virion previously thought to lack N antigenic sites do ex-
hibit a neutralizing determinant. This raises the possibility that
neutralizing antibodies could be induced by subunits of the
virions and not only by the intact mature virion.
The determination of which of the poliovirus proteins can
elicit a neutralizing response has proven elusive. The poliovi-
rion contains four capsid proteins: VP1, VP2, VP3, and VP4.
Neutralizing sera raised against mature virus and the mono-
clonal antibody do not recognize any of the capsid proteins se-
lectively (9). The conversion of N-reactive virions to C-reactive
particles is typically accompanied with the loss of VP4, sug-
gesting initially that VP4 might be the neutralizing determinant
(10, 11). Topological studies, however, indicate that VP4 is not
located at the capsid surface (12). Several attempts to raise a
neutralizing antiserum by using single isolated capsid proteins
have yielded equivocal results. In one study, none of the anti-
sera raised against VP1, VP2, VP3, or VP4 were neutralizing
(13). In a more recent study, the antiserum from only one out
of two rabbits injected with VP1 showed any neutralizing ac-
tivity (14). The antigenic specificity of the antiserum was not
characterized further.
We present here data showing that all rats injected with iso-
lated VP1 develop neutralizing antibodies to poliovirus. Rats
injected with VP2 or VP3 generate antibodies that precipitate
the cognate proteins and bind to virions but have no neutralizing
ability.
METHODS
Production and Isolation of Poliovirus Capsid Proteins.
Poliovirus type 1 (Mahoney) was isolated from infected HeLa
cells. The capsid proteins VP1, VP2, and VP3 were isolated by
NaDodSO4/polyacrylamide gel electrophoresis (15). The vi-
rions were disrupted by boiling for 10 min in 1% NaDodSO4/
5 mM EDTA and then subjected to electrophoresis through a
preparative 13% NaDodSO4/polyacrylamide gel. The sepa-
rated proteins were visualized as clear zones in the gel by pre-
cipitating the free NaDodSO4 in the acrylamide gel with 2.5 M
KC1. The protein bands were cut out and electroeluted over-
night and then dialyzed against 10 mM Tris-HCl, pH 7.5/1 mM
EDTA. The concentrations of the eluted proteins were esti-
mated in polyacrylamide gels by staining intensity relative to
those of protein standards of known concentrations.
Immunizations. Male Lewis rats, 8 wk old (Charles River
Breeding Laboratories), were injected intraperitoneally and in-
tradermally with emulsions containing 100 ,ug of the isolated
proteins. To equalize variability among the individual rats, each
protein was injected into three rats. The emulsions were made
by mixing equal volumes of the protein solution and complete
Freund's adjuvant. After 3 wk, the initial injection was followed
by three booster injections 2 wk apart. Each booster injection
contained 100 ,ug ofprotein in a 50% emulsion with incomplete
Freund's adjuvant. Animals were bled from the ocular sinus 8-
10 days after each booster injection. Sera were heated to 65°C
for 30 min before storage at -20°C. They were checked for the
presence ofantibodies against the injected antigen using Oucht-
erlony double-diffusion plates.
Neutralizing Titers. The titer of neutralizing antibody pres-
ent in antisera was measured by two methods. (i) Half neutral-
ization value: Serial dilutions (1:2) of serum in phosphate-buff-
ered saline were incubated with 200 plaque-forming units (pfu)
ofpoliovirus in a final volume of 200 1. for 2 hr at 25°C and then
overnight at 4°C. The entire sample was placed undiluted on
HeLa cell monolayers in a standard plaque assay protocol. Neu-
tralizing titer was defined as the serum dilution required to re-
duce the number of plaques by 50%. (ii) To quantitate the
amount ofvirus that could be killed by a given amount ofserum,
poliovirus (107 pfu) was incubated with different dilutions ofthe
rat serum in a final volume of 10 ,ul at 25°C for 2 hr and then
overnight at 4°C. The number of surviving infectious particles
was then measured in a standard plaque assay.
Abbreviations: pfu, plaque-forming unit(s); Staph A, Staphylococcus
aureus; FMDV, foot-and-mouth disease virus.
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Plaque Assays. The virus titers were determined using a
cloned HeLa cell line S-3 that is carried in suspension but will
also grow on plates. HeLa cells were plated at 2 x 106/60-mm
plate in Dulbecco's modified medium/5% fetal calf serum.
After 3 hr at 370C, the medium along with any floating cells was
removed by aspiration and 200 1.d of the virus dilution (in phos-
phate-buffered saline) was placed on the monolayer. The plates
were incubated for 30 min at 370C. The plates were then over-
layed with 5 ml of 1% agarose in Dulbecco's modified medium/
5% fetal calf serum and incubated at 370C for 36 hr (polio type
1, Mahoney) or for 54-72 hr (polio type 2, Lansing). All plaque
assays were carried out in duplicate and plaques were visualized
by staining with crystal violet.
[3S]Methionine-Labeled Virions. HeLa cells in medium
lacking methionine were infected with poliovirus at a multi-
plicity of 10 pfu per cell. Cells were labeled with [3S]methionine
(New England Nuclear; specific activity, 850 Ci/mmol; 1 mCi/
liter; 1 Ci = 3.7 x 1010 becquerels) 3.5 hr after infection and
harvested 6 hr after infection. Cells were lysed in 1% Nonidet
P40/10 mM Tris-HCl, pH 7.5/10 mM NaCl/1.5 mM MgCl2
and nuclei were removed by centrifugation., The virus was col-
lected by centrifugation in a 50 Ti rotor for 1 hr at 45,000 rpm.
The virus pellet was suspended in 10 mM Tris HCl, pH 7.5/
1 mM EDTA/0.1 M NaCl/0.5% NaDodSO4 (TNE buffer/
0.5% NaDodSO4) and banded in CsCl. The virus band was
isolated, dialyzed against TNE buffer, and stored at -200C.
Immunoprecipitations. Immunoprecipitations were carried
out in 10mM Tris HCl, pH 7.5/0.15 M NaCl/1% deoxycholate/
1% Triton X-100/0. 1% NaDodSO4 (Ripa buffer) in the presence
of ovalbumin at 0.5 mg/ml. In some cases, just prior to incu-
bation with the antisera, samples were denatured by boiling for
10 min in 1% NaDodSO4/5 mM EDTA and then centrifuged
for 5 min in an Eppendorf centrifuge. [3S]Methionine-labeled
samples were incubated with a given amount of antiserum for
2 hr at room temperature and then for 30 min at 0°C with 10
times the serum volume of a 10% solution of formalin-fixed
Staphylococcus aureus (Staph A) (New England Enzyme Cen-
ter, Boston; Iggsorb). The Staph A was collected by centrifu-
gation for 30 sec in an Eppendorf centrifuge, washed with three
1-ml portions of Ripa buffer/0.5 M NaCl and then with 1 ml
of Ripa buffer/0. 15 M NaCl. Staph A-containing samples were
boiled in the NaDodSO4 sample buffer for 10 min; the Staph
A was removed by centrifugation and the supernatants were
analyzed by electrophoresis through an 11% NaDodSO4/poly-
acrylamide gel (15). The gels were fixed in 10% acetic acid/
10% methanol, dried, and autoradiographed (Kodak, XAR film)
at - 700C.
RESULTS'
Antisera Reactive with Individual Polypeptides. To study
the antigenicity of poliovirus proteins VP1, VP2, and VP3, they
were isolated and individually injected into rats, and serum
samples were collected after each boost. The sera formed pre-
cipitin lines with the injected antigen in Ouchterlony double-
diffusion assays (data not shown).
To test the specificity and selectivity of these antisera against
denatured poliovirus capsid proteins, [3S]methionine-labeled
poliovirions (Mahoney, type 1) were boiled in 1% NaDodSO4
and then immunoprecipitated with the sera. The precipitated
samples were displayed by electrophoresis through an 11%
polyacrylamide gel and detected by autoradiography (Fig. 1A).
Antisera raised against VP1 specifically precipitated the VP1
released from dissociated virions (lanes 3 and 4). Similarly, anti-
sera raised against VP2 or VP3 precipitated only VP2 or VP3,
respectively (lanes 6, 7, 9, and 10). None of the preimmune rat
sera precipitated any specific virion proteins (lanes 2, 5, and 8).
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FIG. 1. Immunoprecipitation of NaDodSO4-denatured and native
virions with a-VP1, a-VP2, or a-VP3 serum. (A) [35S]Methionine-la-
beled virions were boiled for 10 min in the presence of 1% NaDodSO4/
5 mM EDTA, and insoluble material was removed by centrifugation
in an Eppendorf centrifuge for 10 min. The virions were precipitated
with 5 'l of preimmune serum (lanes 2, 5, and 8) or with 2 jul (lanes
3, 6, and 9) or 5 tL. (lanes 4, 7, and 10) of -immune serum. Serum in-
cubations were;done in the presence of Ripa buffer for 2-hr at room
temperature, formalin-fixed Staph A was added, and the mixture was
incubated for 1 hr at 40C. To monitor nonspecific background adsorp-
tion of the virion proteins to the Staph A, labeled virions were incu-
bated with Staph A without addition of any serum (lane 1). [35S]_
Methionine-labeled virions were analyzed as markers (lane 11). (B)
[35S]Methionine-labeled virions were immunoprecipitated with 5 Aul
of preimmune serum (lanes 1, 4, and 7) or with 2 1.l (lanes 2, 5, and
8) or 4 p.l (lanes 3, 6, and 9) of a-VP1, a-VP2, or a-VP3 serum. The
different intensities of VP1, VP2, and VP3 bands reflects the methi-
onine content of each protein.
In every gel, several dilutions of [3-S]methionine-labeled vi-
rions at known protein concentrations and specific activity were
displayed as protein standards. By comparing the intensities of
the immunoprecipitated bands with those of the virion stan-
dards, an estimate was made ofthe number ofantigen molecules
precipitated by a known volume of serum. After the second
boost, 2 A.l of almost all of the rat sera precipitated a quantity
of capsid protein equivalent to that found in 1010 particles. Be-
cause there are 60 molecules of each capsid protein in a virion,
this represents almost 1012 molecules of antigen. Thus, each
antiserum contains high titers of antibodies that are specific to
only one capsid protein. The sera will be designated a-VP1, a-
VP2, and a-VP3.
To test whether the sera recognized any antigenic determi-
nants on native virions, immunoprecipitations were done using
[35s]methionine-labeled virions that had not been boiled in
NaDodSO4 (Fig. 1B). All of the antisera precipitated intact vi-
rions, although with various efficiencies. By comparing the in-
tensities against virion standards, 2 1.l of a-VP1 or a-VP2 pre-
cipitated approximately 109 virion particles and 2 A.l of a-VP3
precipitated approximately 10 virions. Thus, only a small frac-
tion of the antibodies produced against the denatured virion
proteins recognized and bound to the proteins in their native
state.
Neutralization Activity of Sera. Because the antisera rec-
ognized antigenic determinants on intact virions, they were
tested for neutralizing activity. In one test, 200 pfu of poliovirus
was incubated with 1:2 serial dilutions ofserum and the number
of surviving pfu was measured with a plaque assay. The titers
for neutralization of one-half of the input virions showed that
only a-VPl contained any neutralizing activity (Table 1). Even
after a third boost, a-VP2 and a-VP3 showed no neutralization
activity. In contrast, after each boost with VP1, the neutralizing
titers of a-VPl increased such that, after the third boost with
Medical Sciences: Chow and Baltimore
7520 Medical Sciences: Chow and Baltimore
Table 1. Production of neutralizing serum in rats inoculated with isolated poliovirus
type 1 proteins
50% neutralization titer of sera
Polio type 1
Preimmune First Second Third Polio type 2
Antigen Rat serum bleeding bleeding bleeding (third bleeding)
VP1 1 0 1/2 1/5 1/30 0
2 0 1/10 1/50 1/200 0
3 0 1/4 1/6 1/60 0
VP2 4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
VP3 7 0 0 0 0 0
8 0 0 0 0 0
9 0 0 0 0 0
Virions 10 0 >104 0.6 x 103*
11 0 >104 1 X 103*
12 0 >104 0.8 x 103*
* Determined on serum from the first bleed.
VP1, serum neutralizing titers had increased 10-fold over the
titer obtained after the first boost. Although a-VP1, a-VP2, and
a-VP3 immunoprecipitate VP1, VP2, and VP3 from poliovirus
type 2 virions, respectively (data not shown), none of the rat
antisera showed any neutralization activity against poliovirus
type 2.
Because the serum titers were very low and neutralization
activity was observed only with undiluted or very low dilutions
of serum, a second neutralization protocol was used to test for
the possibility of nonspecific inhibition. To this end, a high-titer
stock of poliovirus was incubated with antiserum and the re-
maining virus was assayed after extensive dilution (Table 2). No
significant neutralization was apparent when 5 x 107 pfu of
poliovirus was incubated with undiluted preimmune sera, a-
VP2, or a-VP3. In contrast, virus decreased by approximately
1.5 log1o when incubated with a-VP1 serum. Thus, rats injected
with a single capsid protein, VP1, produce sera that are capable
of neutralizing poliovirions. Also significant is the observation
that all rats that were injected with VP1 generated neutralizing
antibodies.
Anti-Virion Antibodies. Because the neutralizing titers of a-
VP1 appeared low, the neutralizing titers of sera from rats in-
jected with whole virions (a-Vir) were measured as a standard
ofcomparison. As expected, the a-Vir titers after the first boost
were several orders of magnitude higher than the a-VP1 titers
achieved after the third boost (Tables 1 and 2).
Table 2. Effect of undiluted rat sera on 5 x 107 pfu of poliovirus
type 1
Virus titer after incubation with sera
from each bleeding (x 10-7)
Preimmune
Antigen Rat serum First Second Third
VP1 2 5.0 1.0 0.5 0.1
VP2 4 5.0 5.0 5.0
5 5.0 4.0
VP3 7 5.0 6.0 5.0
8 4.0
Virions 10 5.0 0.04*
11 4.0 0.1*
12 5.0 0.03*
* A serum dilution of 10-3 was used for this test.
To test the ability of a-Vir to bind to capsid proteins in their
natural or denatured conformations, native and NaDodSO4-
denatured virions were immunoprecipitated with a-Vir sera
(Fig. 2). Consistent with the high neutralizing titers observed,
the antisera quantitatively precipitated native virions (Fig. 2,
lanes 1-6). Thus, after the first boost, 2 dul of serum could im-
munoprecipitate approximately 1010 virion particles. None of
the a-Vir sera, however, recognized any of the denatured pro-
teins (Fig. 2, lanes 7-12). Thus, antisera induced by virions ap-
pear to recognize different antigenic determinants than antisera
raised against the individual proteins.
All antisera (a-VP1, a-VP2, a-VP3, and a-Vir) recognized
and immunoprecipitated the capsid protein intracellular pre-
cursors from infected cell lysates in the absence of extensive
denaturation (data not shown).
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FIG. 2. Immunoprecipitation of NaDodSO4-denatured and native
virions with a-Vir serum. [35S]Methionine-labeled virions, NaDodSO4
denatured or intact, were precipitated with a-Vir sera from two rats
(rat 10 and rat 11). Background absorption when virions were incu-
bated with Staph A alone is shown in lane 13. Denatured virions were
precipitated with 10 ,ul of preimmune serum (lanes 7 and 10) or with
5 or 10 jil of immune serum (lanes 8 and 11 and lanes 9 and 12, re-
spectively). Intact virions were precipitated with 5 .1A of preimmune
serum (lanes 1 and 4) or with 2 or 5 t.l of immune serum (lanes 2 and
5 and lanes 3 and 6, respectively).
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DISCUSSION
Although most previous work on poliovirus neutralization has
implied that only intact virions can elicit a neutralizing re-
sponse, it is evident that rat sera prepared against a single poly-
peptide of the poliovirion, VP1, contain neutralizing antibody.
Because comparable antisera against VP2 and VP3 had no neu-
tralizing activity, it appears that only VP1 can stimulate a neu-
tralizing response under our conditions of immunization. The
neutralizing response to VP1 is much weaker than the response
to virions but it is serotype specific and in this way mimics the
response to virions.
The ability of poliovirus VP1 to elicit a neutralizing response
might have been expected because the equivalent foot-and-
mouth disease virus (FMDV) and mengovirus polypeptides
have previously been shown to elicit such a response (16-21).
Like poliovirus, these are picornaviruses although of the
aphthovirus and cardiovirus subgroups rather than the entero-
virus subgroup (22). Possibly all picornaviral VP1s would induce
such a response.
Although a-VP2 and a-VP3 did not contain neutralizing an-
tibodies, they did react with intact virions, implying that de-
terminants of both VP2 and VP3 are on the viral surface. Pre-
vious radiolabeling and cross-linking studies had led to similar
conclusions (12, 23).
Although VP1 clearly contains a neutralizing determinant,
it is probably not the same neutralizing determinant to which
the a-Vir antibodies bind because such antiserum did not im-
munoprecipitate the isolated proteins. In addition, hybridoma
cell lines have been isolated in other laboratories from mice in-
jected with poliovirions that produce neutralizing antibodies.
These antibodies do not recognize VP1 from disrupted virions
(9). Both lines of evidence suggest that the neutralizing deter-
minants recognized by the a-Vir sera and a-VP1 are not iden-
tical.
The induction of neutralizing antibodies and the neutral-
ization process are poorly understood phenomena, and the
weakness of the neutralizing response elicited by isolated polio-
virus VP1 could be due to many factors. Neutralizing antibodies
must recognize the poliovirus proteins in their native confor-
mation so that the NaDodSO4-denatured VP1 protein may be
less efficient than nondenatured VP1 protein for generating
antibodies that recognize the native conformation. Also, the
presence ofthe other capsid proteins (VP2 and VP3) in the virion
may modify or alter the antibody response of the host to VP1.
The interaction of VP1 with VP2 and VP3 may restrict the con-
formation of VP1 such that, in the presence of VP2 and VP3,
the major VP1 immunogenic conformation of the neutralizing
determinant presented to the animal is that recognized by the
neutralizing antibodies. Alternatively, the association of VP2
and VP3 with VP1 may block or shield VP1 immunogenic sites
that are predominant in the denatured VP1 protein. Thus, a
higher proportion of the VPl-reactive antibodies generated in
the a-Vir sera may be directed toward the VP1 neutralizing site.
Finally, neutralizing antibodies raised from intact poliovirions
may actually recognize VP1 in a complex with VP2 and VP3;
hence these antibodies may be more efficient in neutralizing
poliovirus than antibodies solely directed against VP1.
The existence of a-VP1 sera that bind to intact virions may
allow the neutralization process to be studied in finer detail.
Recent studies with FMDV have shown that the binding of
FMDV virions to the cellular receptor is dependent on the cor-
responding VP1 protein from FMDV (24). Trypsin treatment
of FMDV leaves the virion intact structurally, but the VP1 pro-
tein has been cleaved. The trypsinized FMDV is unable to bind
to isolated plasma membranes containing the virus receptor or
to intact cells. The observations that the poliovirus VP1 is ca-
pable of eliciting a neutralizing response suggests that this pro-
tein may be similarly responsible for mediating virus interac-
tions with the cellular receptor. Thus, one possible mechanism
of virus neutralization is that the neutralizing antibody to VP1
prevents the virus from binding to the cellular receptor.
The demonstration that VP1 can stimulate a neutralizing re-
sponse suggests that it may be possible to produce a poliovirus
vaccine using only VP1 determinants. The neutralizing re-
sponse seen thus far in rats is probably too low to be protective
but, by appropriate manipulations, a more immunogenic form
of VP1 might be found. One promising route to producing such
a subunit vaccine would be the use of synthetic peptides rep-
resenting the VP1 sequence (20).
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